title: Bilateral uveitis associated with fluoroquinolone therapy.
abstract: BACKGROUND
  Retrospective case series, database study and literature review. Forty case reports are described.
  
  
  OBJECTIVE
  To report a possible association between fluoroquinolones and uveitis.
  
  
  METHODS
  Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects, World Health Organization, and Food and Drug Administration were collected on uveitis associated with systemic fluoroquinolone therapy. A literature review was performed using keywords "uveitis", "fluoroquinolones", and each individual fluoroquinolone name. Additional case reports were collected from the practices of six uveitis subspecialists and one neuro-ophthalmologist.
  
  
  METHODS
  Data garnered from the reports include the type of fluoroquinolone, age, gender, adverse drug reaction (ADR), dosage, duration of therapy until onset of uveitis, concomitant drugs, systemic disease, dechallenge and rechallenge data.
  
  
  RESULTS
  A total of 40 case reports of uveitis associated with fluoroquinolones were identified including 12 men, 27 women, and 1 case in which the gender was not specified. The median age was 54 years. Dosage varied between the different fluoroquinolone drugs, with the median dosage within the range recommended in the package insert for each different fluoroquinolone. Median time from beginning of therapy to appearance of the ADR was 13 days (range 0-20 days). Thirteen patients were 60 years or older, and one patient was taking systemic anti-inflammatory steroids. There were five positive dechallenge case reports.
  
  
  CONCLUSIONS
  According to World Health Organization criteria, the relationship between fluoroquinolone therapy and uveitis is "possible". Causality assessments are based on the time relationship of drug administration, uveitis development, and dechallenge data.
  
  
  CONCLUSIONS
  Clinicians should be aware of a possible bilateral fluoroquinolone-associated uveitis, particularly the finding of iris transillumination and pigment dispersion.
authors: MERSI, 5, Cambridge Center, 8th Floor, Cambridge, NY 02142, USA. dmh15@case.edu
authors: David M
authors: DM
authors: Hinkle
authors: Mark S
authors: MS
authors: Dacey
authors: Efrem
authors: E
authors: Mandelcorn
authors: Partho
authors: P
authors: Kalyani
authors: John
authors: J
authors: Mauro
authors: James H
authors: JH
authors: Bates
authors: Sarkis H
authors: SH
authors: Soukasian
authors: Gary N
authors: GN
authors: Holland
authors: C Stephen
authors: CS
authors: Foster
authors: Frederick T
authors: FT
authors: Fraunfelder
authors: Janet L
authors: JL
authors: Davis
authors: Frederick W
authors: FW
authors: Fraunfelder
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010031:Otitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012189:Retrospective Studies; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014605:Uveitis / Q000139:chemically induced*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones